PharmGKB ID	Variant	Literature	Genes	Association	Significance	P-Value	# of Cases	# of Controls	Biogeographical Groups	Phenotype Categories	Pediatric	More Details	Drugs
1452058509	CYP3A5*1; CYP3A5*3	PMID:36973144	CYP3A5	CYP3A5 *3/*3 + *1/*3 is associated with increased likelihood of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.	not stated		24		Central/South Asian		false	"""New-onset diabetes after transplantation was seen in 28.6% of patients in the non-expresser group and 12.5% of the intermediate expresser group."" zero out of the two *1/*1 (""expressers"") had NODAT."	tacrolimus
1448569429	rs7661530	PMID:28084903	KCNIP4	Allele T is not associated with Cough when treated with Ace Inhibitors, Plain in people with Asthma, Diabetes Mellitus, Heart Failure, Hypertension or Pulmonary Disease, Chronic Obstructive as compared to allele C.	no	= 0.25	124	1345	European	Toxicity	false		Ace Inhibitors, Plain
731577503	rs2368564	PMID:18794727	REN	Genotype TT is associated with decreased risk of Edema when treated with muraglitazar in people with Diabetes Mellitus as compared to genotype CC.	yes	= 0.003	155	117	Unknown	Toxicity	false		muraglitazar
1183680651	rs1057868	PMID:24113216	POR	Genotypes CT + TT are associated with increased risk of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	yes	= 0.03	85		Unknown	Toxicity	false	Association with the development of new-onset diabetes after transplantation. All patients received a triple-drug immunosuppressive regimen, consisting of Tac, MMF, and prednisolone. The POR*28 allele (rs1057868; POR*28; A503V) was associated with an increased risk of developing NODAT.	tacrolimus
1444666909	rs2241767	PMCID:PMC4236071	ADIPOQ	Genotype AA are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotypes AG + GG.	no	= 0.826	80		East Asian	Efficacy	false	"Response was defined as ""any decrease greater than (or equal to) 15%"" of glycated hemoglobin (HbA1C%)."	pioglitazone
1452288920	rs776746	PMID:37891021	CYP3A5	Allele T is associated with increased likelihood of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to allele C.	yes	= 0.015	44	200	East Asian	Toxicity	false	"Alleles complemented. ""the frequency of the A allele was significantly higher in the PTDM group compared to the control group, whereas the G allele was more prevalent in the control group"""	tacrolimus
1450377081	rs290487	PMID:23041303	TCF7L2	Genotypes CC + CT is associated with increased risk of Diabetes Mellitus when treated with tacrolimus in people with liver transplantation as compared to genotype TT.	yes	= 0.015	125		East Asian	Toxicity	false	When looking at DONOR genotype. New-onset diabetes mellitus (NODM). OR value is per C allele. Significant results were also seen when looking at donor+recipient genotype (p=0.005, OR=2.466), but recipient genotype alone was only significant in univariate analysis when comparing CC vs TT genotype (p=0.034, OR=1.94).	tacrolimus
1183680640	rs4253728	PMID:24113216	PPARA	Genotypes AA + AG are associated with increased risk of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.	yes	= 0.03	85		Unknown	Toxicity	false	"Association with the development of new-onset diabetes after transplantation. All patients received a triple-drug immunosuppressive regimen, consisting of Tac,
MMF, and prednisolone."	tacrolimus
1447679323	rs2167270	PMID:26282401	LEP	Allele A is associated with increased likelihood of Diabetes Mellitus when treated with cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.	yes	= 0.000035	229		European	Toxicity	false	This was more significant in the subset of tacrolimus-treated patients but not significant in the smaller subset of cyclosporine-treated patients.	cyclosporine; tacrolimus
1452364162	rs2740574	PMID:38253626	CYP3A4	Genotypes CC + CT is associated with decreased likelihood of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to genotype TT.	yes	= 0.026	37	183	Near Eastern	Toxicity	true	"""The CYP3A4*1B
allele was significantly associated to a lower occurrence of newonset diabetes (OR = 0.60, 95% CI: 0.38–0.94, p = 0.026)."" Mapped CYP3A4*1B to rs2740574C and CYP3A4*1 to rs2740574T."	tacrolimus
1449751674	rs1204964501	PMCID:PMC6563124	CACNA1S	Allele G is associated with statin-related myopathy when treated with atorvastatin in people with Diabetes Mellitus and Hypertension as compared to allele C.	no		1		European	Toxicity	false	Alleles complemented to plus chromosomal strand. While study looked at 76 subjects with severe statin-associated muscle symptoms and 50 statin-tolerant controls, then studied exam sequencing data in RYR1 and CACNA1S, most variants considered pathogenic were at very low frequency and were reported as case series not with statistics for overall risk.	atorvastatin
1296666461	rs4810083	PMID:25327507	PCK1	Allele T is not associated with response to metformin in people with Diabetes Mellitus as compared to allele C.	no	= 0.180	148		Unknown	Efficacy	false	Treatment success was defined as 1) achieving HbA1c <7 % and 2) absolute reduction in HbAlc after 6-months of metformin therapy. The relationships between genotypes and outcomes were evaluated using multivariate logistic and linear models.	metformin
769169088	rs5030952	PMID:19752882	CAPN10	Genotype CT is associated with increased risk of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	yes	= 0.023	56	158	Unknown	Toxicity	false	The subjects had kidney transplants.  There were not enough TT to draw a conclusion.  Haplotypes with rs3792267 and rs3842570 were also important.	tacrolimus
769171392	rs5443	PMID:19247266	GNB3	Genotype CC is associated with increased risk of Diabetes Mellitus when treated with Thiazides, plain as compared to genotypes CT + TT.	yes	< 0.05	497	2633	European	Toxicity	false	Referred to as GNB3 C825T. The study compared  CC genotype OR; 2.01 (1.49-2.72) p<0.05, with CT/TT genotype OR; 1.36 (1.01-1.84) p<0.05, and showed that carriers of the CC genotype had a significantly higher increased risk.	Thiazides, plain
1448267848	rs2617102	PMCID:PMC5534241	CSMD1	Genotypes AC + CC is associated with decreased response to metformin in people with Diabetes Mellitus as compared to genotype AA.	yes	= 0.02	1056		Multiple groups	Efficacy	false	using computational model-based approaches and genetic, demographic, and long-term HbA1c data from 1,056 patients.	metformin
1184470146	rs757110	PMID:24442125	ABCC8	Allele C is not associated with decreased hemoglobin levels when exposed to glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele A.	no	= 0.724	156		European	Toxicity	false	Fasting blod sample was drawn to determine hemoglobin (A1c) levels. HbA1c was determined with immunoturbodimetric hemolytic automated analysis/.	gliclazide; glimepiride; glipizide; gliquidone; glyburide
769171399	rs5186	PMID:19247266	AGTR1	Genotypes AA + AC is associated with increased risk of Diabetes Mellitus when treated with Thiazides, plain as compared to genotype CC.	yes	< 0.05	497	2633	European	Toxicity	false	Referred to in the study as A1166C. The study compared AA/ AC genotype OR;1.79 (1.43-2.23) p<0.05, to the CC genotype OR; 0.63 (0.28-1.4) p<0.05 and showed that carriers of the A allele have a significantly higher increased risk.	Thiazides, plain
1449183040	CYP3A5*1; CYP3A5*3	PMID:29399716	CYP3A5	CYP3A5 *1/*1 + *1/*3 is not associated with risk of Diabetes Mellitus when treated with tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	no	= 0.386	18	80	Unknown	Toxicity	true	No difference in allele frequencies was found between children who developed post-transplant diabetes mellitus (PTDM) and those who did not.	tacrolimus
1448569459	rs16870989	PMID:28084903	KCNIP4	Allele A is not associated with Cough when treated with Ace Inhibitors, Plain in people with Asthma, Diabetes Mellitus, Heart Failure, Hypertension and Pulmonary Disease, Chronic Obstructive as compared to allele T.	no	= 0.72	124	1345	European	Toxicity	false		Ace Inhibitors, Plain
1448569470	rs145489027	PMID:28084903	KCNIP4	Allele A is not associated with Cough when treated with Ace Inhibitors, Plain in people with Asthma, Diabetes Mellitus, Heart Failure, Hypertension and Pulmonary Disease, Chronic Obstructive as compared to allele G.	no	= 0.72	124	1345	European	Toxicity	false		Ace Inhibitors, Plain
1451141460	rs4149056	PMID:32361904	SLCO1B1	Genotypes CC + CT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype TT.	yes	= 0.001	269		East Asian	Metabolism/PK	false	This variant affected rosuvastatin concentration significantly and potentially affect serum levels of pro-inflammatory and pro-angiogenic markers.	rosuvastatin
982035107	rs4253778	PMID:15608561	PPARA	Genotype GG is associated with increased response to fenofibrate in people with Diabetes Mellitus as compared to genotypes CC + CG.	yes	= 0.013	155		Unknown	Efficacy	false	"Patients with the GG genotype were more likely to be a ""high responder"" to fenofibrate treatment. High responders were classified as having a relative reduction of triglyceride levels > 30% after at least 3 years of fenofibrate treatment. Patients with less than or equal to 30% reduction in triglyceride levels were classified as ""low responders""."	fenofibrate
827788923	rs12943590	PMCID:PMC3329222	SLC47A2	Genotype AA is associated with decreased response to metformin in people with Diabetes Mellitus as compared to genotypes AG + GG.	yes	= 0.002	189		European	Efficacy,Metabolism/PK	false		metformin
1449183053	rs1045642	PMID:29399716	ABCB1	Genotypes AG + GG is not associated with risk of Diabetes Mellitus when treated with tacrolimus in children with Kidney Transplantation as compared to genotype AA.	no	= 0.066	18	80	Unknown	Toxicity	true	No difference in allele frequencies was found between children who developed post-transplant diabetes mellitus (PTDM) and those who did not. The authors note that the cumulative proportion of patients developing PTDM was higher in those who carried the AG and GG genotype and the rs1057868 TT genotype (p=0.012). Please note that alleles have been complemented to the plus chromosomal strand.	tacrolimus
1444666932	rs266729	PMCID:PMC4236071	ADIPOQ	Genotype CC are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotypes CG + GG.	no	= 0.856	80		East Asian	Efficacy	false	"Response was defined as ""any decrease greater than (or equal to) 15%"" of glycated hemoglobin (HbA1C%)."	pioglitazone
1449751643	rs757284447	PMCID:PMC6563124	RYR1	Allele T is associated with statin-related myopathy when treated with atorvastatin in people with Diabetes Mellitus as compared to allele C.	no		1		European	Toxicity	false	While study looked at 76 subjects with severe statin-associated muscle symptoms and 50 statin-tolerant controls, then studied exam sequencing data in RYR1 and CACNA1S, most variants considered pathogenic were at very low frequency and were reported as case series not with statistics for overall risk.	atorvastatin
1444666920	rs3821799	PMCID:PMC4236071	ADIPOQ	Genotypes CT + TT are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotype CC.	no	= 0.908	80		East Asian	Efficacy	false	"Response was defined as ""any decrease greater than (or equal to) 15%"" of glycated hemoglobin (HbA1C%).  The TT genotype was associated with a greater decrease in waist circumference as compared to the TC and CC genotypes after pioglitazone therapy (p=0.033)."	pioglitazone
1449183060	rs2228570	PMID:29399716	VDR	Genotypes AA + AG is not associated with risk of Diabetes Mellitus when treated with tacrolimus in children with Kidney Transplantation as compared to genotype GG.	no	= 0.443	18	80	Unknown	Toxicity	true	No difference in allele frequencies was found between children who developed post-transplant diabetes mellitus (PTDM) and those who did not.	tacrolimus
1444666926	rs3774261	PMCID:PMC4236071	ADIPOQ	Genotypes AG + GG are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotype AA.	no	= 0.856	80		East Asian	Efficacy	false	"Response was defined as ""any decrease greater than (or equal to) 15%"" of glycated hemoglobin (HbA1C%).  The AA genotype was associated with a greater decrease in waist circumference as compared to the AG and GG genotypes after pioglitazone therapy (p=0.019) although the AG and GG genotypes were associated with a greater decrease in fasting insulin as compared to the AA genotype (p=0.03)."	pioglitazone
1448267876	rs2954625	PMCID:PMC5534241	CSMD1	Genotypes CT + TT are associated with decreased response to metformin in people with Diabetes Mellitus as compared to genotype CC.	yes	= 0.029	1056		Multiple groups	Efficacy	false	using computational model-based approaches and genetic, demographic, and long-term HbA1c data from 1,056 patients.	metformin
1449183067	rs731236	PMID:29399716	VDR	Genotypes AA + AG is not associated with risk of Diabetes Mellitus when treated with tacrolimus in children with Kidney Transplantation as compared to genotype GG.	no	= 0.282	18	80	Unknown	Toxicity	true	No difference in allele frequencies was found between children who developed post-transplant diabetes mellitus (PTDM) and those who did not.	tacrolimus
1451141440	rs2231142	PMID:32361904	ABCG2	Genotypes GT + TT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype GG.	yes	= 5.75e-4	269		East Asian	Metabolism/PK	false	This variant affected rosuvastatin concentration significantly and potentially affect serum levels of pro-inflammatory and pro-angiogenic markers.	rosuvastatin
1448569448	rs7675300	PMID:28084903	KCNIP4	Allele A is not associated with Cough when treated with Ace Inhibitors, Plain in people with Asthma, Diabetes Mellitus, Heart Failure, Hypertension and Pulmonary Disease, Chronic Obstructive as compared to allele C.	no	= 0.72	124	1345	European	Toxicity	false		Ace Inhibitors, Plain
1447676681	rs10783050	PMID:26401715		Genotype TT is associated with increased response to metformin in people with Diabetes Mellitus as compared to genotypes CC + CT.	yes	= 0.043	107		East Asian	Efficacy	false	as measured by decreased HbA1c. Discovery population (which also received glibenclamide or chinese medicine containing glibenclamide) also saw decreases in hip circumference.	metformin
1447676673	rs1143623	PMID:26401715	IL1B	Genotype GG is associated with increased response to metformin in people with Diabetes Mellitus as compared to genotypes CC + CG.	yes	= 0.004	85		East Asian	Efficacy	false	as measured by decreased HbA1c. Discovery population (which also received glibenclamide or Chinese medicine containing glibenclamide) also saw decreases in waist, hip circumference and BMI.	metformin
1449748000	CYP3A5*1; CYP3A5*3	PMID:29546446	CYP3A5	CYP3A5 *1 is not associated with risk of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.	no	= 0.65	169		East Asian	Toxicity	false	New-onset diabetes after transplantation (NODAT).	tacrolimus
1296666368	rs3792269	PMID:25327507	CAPN10	Allele G is associated with decreased response to metformin in people with Diabetes Mellitus as compared to allele A.	yes	= 0.02	144		Unknown	Efficacy	false	Treatment success was defined as 1) achieving HbA1c <7 % and 2) absolute reduction in HbAlc after 6-months of metformin therapy. The relationships between genotypes and outcomes were evaluated using multivariate logistic and linear models.	metformin
769180562	rs2237895	PMID:21355884	KCNQ1	Genotype CC is associated with increased risk of Diabetes Mellitus when treated with tacrolimus in people with cadaveric kidney graft as compared to genotype AA.	not stated	= 0.017	145		European	Toxicity	false	Association with new-onset diabetes after transplantation.	tacrolimus
1444666960	rs1063537	PMCID:PMC4236071	ADIPOQ	Genotype CC are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotypes CT + TT.	no	= 0.235	80		East Asian	Efficacy	false	"Response was defined as ""any decrease greater than (or equal to) 15%"" of glycated hemoglobin (HbA1C%)."	pioglitazone
1444666966	rs2082940	PMCID:PMC4236071	ADIPOQ	Genotype CC are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotypes CT + TT.	no	= 0.719	80		East Asian	Efficacy	false	"Response was defined as ""any decrease greater than (or equal to) 15%"" of glycated hemoglobin (HbA1C%)."	pioglitazone
982035143	rs708272	PMID:15608561	CETP	Genotype AA is not associated with response to fenofibrate in people with Diabetes Mellitus.	no		155		Unknown	Efficacy	false	"Response was assessed by reduction in triglyceride levels after at least 3 years of fenofibrate treatment. ""High responders"" had a relative reduction of triglyceride levels > 30%, ""low responders"" had a relative reduction less than or equal to 30%. No significant differences in the percentages of high and low responders were seen between genotypes."	fenofibrate
1449183025	rs1057868	PMID:29399716	POR	Genotypes CC + CT is not associated with risk of Diabetes Mellitus when treated with tacrolimus in children with Kidney Transplantation as compared to genotype TT.	no	= 0.114	18	80	Unknown	Toxicity	true	No difference in allele frequencies was found between children who developed post-transplant diabetes mellitus (PTDM) and those who did not. The authors note that the cumulative proportion of patients developing PTDM was higher in those who carried the TT genotype and the rs1045642 AG or GG genotypes (p=0.012).	tacrolimus
1448602371	rs11124945	PMCID:PMC5368017	PLEKHH2	Allele G is associated with decreased risk of Diabetes Mellitus when exposed to atenolol or verapamil in people with Hypertension as compared to allele A.	yes	= 8.58E-7	138	414	European	Toxicity	false		atenolol; verapamil
1449183033	rs4253728	PMID:29399716	PPARA	Genotypes AG + GG is not associated with risk of Diabetes Mellitus when treated with tacrolimus in children with Kidney Transplantation as compared to genotype AA.	no	= 0.460	18	80	Unknown	Toxicity	true	No difference in allele frequencies was found between children who developed post-transplant diabetes mellitus (PTDM) and those who did not.	tacrolimus
1444666944	rs16861194	PMCID:PMC4236071	ADIPOQ	Genotype AG are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotype AA.	no	= 0.781	80		East Asian	Efficacy	false	"Response was defined as ""any decrease greater than (or equal to) 15%"" of glycated hemoglobin (HbA1C%)."	pioglitazone
608178461	rs622342	PMID:19381165	SLC22A1	Allele C is associated with decreased reduction in HbA1c levels when treated with metformin in people with Diabetes Mellitus.	not stated	= 0.05	102		European	Efficacy	false		metformin
982035158	rs1800206	PMID:15608561	PPARA	Genotype CC is not associated with response to fenofibrate in people with Diabetes Mellitus.	no		155		Unknown	Efficacy	false	"Response was assessed by reduction in triglyceride levels after at least 3 years of fenofibrate treatment. ""High responders"" had a relative reduction of triglyceride levels > 30%, ""low responders"" had a relative reduction less than or equal to 30%. No significant differences in the percentages of high and low responders were seen between genotypes."	fenofibrate
982042071	rs1799752	PMID:11007831	ACE	Genotype del/del is associated with increased response to benazepril or perindopril in people with Diabetes Mellitus as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	yes	< 0.05	83		East Asian	Efficacy	false	Patients with the del/del genotype had significantly greater percentage reductions between baseline and 3 months of treatment in urinary excretion of protein and albumin, as compared to those with the remaining genotypes. This indicates a greater response to the antiproteinuric effects of benazepril and perindopril.	benazepril; perindopril
608178465	rs1801253	PMID:18794727	ADRB1	Genotype GG is associated with increased risk of Edema when treated with muraglitazar in people with Diabetes Mellitus as compared to genotype CC.	not stated	= 0.07	155	117	Unknown	Toxicity	false	GG and GC genotype as reported in paper	muraglitazar
1448267827	rs316009	PMCID:PMC5534241	SLC22A2	Genotype TT is associated with increased response to metformin in people with Diabetes Mellitus as compared to genotypes CC + CT.	yes	= 0.04	1056		Multiple groups	Efficacy	false	using computational model-based approaches and genetic, demographic, and long-term HbA1c data from 1,056 patients.	metformin
1451226140	rs4149056	PMCID:PMC6309567	SLCO1B1	Genotype TT is not associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CC + CT.	no	= 0.71	38	164	Central/South Asian	Toxicity	false		atorvastatin; rosuvastatin
608178470	rs5370	PMID:18794727	EDN1	Genotype GG is associated with decreased risk of Edema when treated with muraglitazar in people with Diabetes Mellitus as compared to genotype TT.	not stated	= 0.012	155	117	Unknown	Toxicity	false	p=0.012 is for GG vs TT	muraglitazar
1449747968	CYP3A4*1; CYP3A4*18	PMID:29546446	CYP3A4	CYP3A4 *1/*18 + *18/*18 are not associated with risk of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	no	= 0.086	169		East Asian	Toxicity	false	New-onset diabetes after transplantation (NODAT). PharmVar has consolidated CYP3A4*18B under CYP3A4*18 .001	tacrolimus
1450342681	rs776746	PMCID:PMC6309567	CYP3A5	Genotype CC is associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CT + TT.	yes	= 0.04	38	164	Unknown	Toxicity	false	Authors play down the significance because it was not significant when looking at atorvastatin or rosuvastatin subsets individually.	atorvastatin; rosuvastatin
1296666425	rs249429	PMID:25327507	PRKAA1	Allele T is not associated with response to metformin in people with Diabetes Mellitus as compared to allele C.	no	= 0.230	144		Unknown	Efficacy	false	Treatment success was defined as 1) achieving HbA1c <7 % and 2) absolute reduction in HbAlc after 6-months of metformin therapy. The relationships between genotypes and outcomes were evaluated using multivariate logistic and linear models.	metformin
1183681016	rs7917983	PMCID:PMC3893755	TCF7L2	Allele T is associated with increased risk of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele C.	yes	= 0.03	941	494	European	Toxicity	false	Hydrochlorothiazide-induced diabetes. Hydrochlorothiazide (HCTZ)  treatment was defined as exposure to HCTZ with any dose or duration before diagnosis of NOD. The patients are part of the INVEST study with randomized treatment with either an atenolol-based or a verapamil sustained release (SR)-based antihypertensive strategy. Both treatment strategies included the possibility of HCTZ treatment at different steps of the treatment plan for BP control as necessary.	hydrochlorothiazide
981754621	rs7903146	PMCID:PMC2799180	TCF7L2	Allele T is associated with increased likelihood of Diabetes Mellitus when treated with cyclosporine, sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele C.	yes	= 0.002	1076		European	Toxicity	false	"The type of Diabetes is termed ""NODAT"" (New-onset diabetes after transplantation).  Authors state that correction for multiple testing was not done because the SNPs were selected on the basis of biological evidence that they were associated with type 2 Diabetes. 11 polymorphisms were tested, and p shown is uncorrected value.  CT compared to CC: 59% higher odds of NODAT (p = 0.03).  TT vs CC: 92% higher odds of NODAT (p = 0.04)."	cyclosporine; sirolimus; tacrolimus
699638985	rs17238540	PMID:18815589	HMGCR	Genotype GT is associated with decreased likelihood of reaching target cholesterol levels when treated with atorvastatin, cerivastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin in people with Diabetes Mellitus as compared to genotype TT.	yes	= 5.0E-4	1601		European	Efficacy	false	Odds ratio for failure to reach target TG vs TT = 2.93 (1.61-5.34). Patients who have had at least 2 statin prescriptions.	atorvastatin; cerivastatin; fluvastatin; pravastatin; rosuvastatin; simvastatin
1449310690	rs316019	PMCID:PMC5898372	SLC22A2	Allele A is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele C.	no	> 0.05	425		Latino	Efficacy	false		sulfonamides, urea derivatives
1448276436	rs4149056	PMID:27271184	SLCO1B1	Allele T is not associated with response to pioglitazone in people with Diabetes Mellitus as compared to allele C.	no	= 0.37	239		Unknown	Efficacy	false		pioglitazone
981344247	rs675388	PMCID:PMC3529742	KCNJ1	Allele A is associated with increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele G.	yes	= 0.004	131		African American/Afro-Caribbean	Toxicity	false		hydrochlorothiazide
1184470034	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMID:24442125	CYP2C9	CYP2C9 *2 + *3 is associated with increased risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to CYP2C9 *1.	yes	= 0.014	103		European	Other	false	"The authors report that the *2 and *3 alleles are not associated with the number of hypoglycemic events per patient over a period of three months when looking at the whole group (N=156). When looking only at patients over 60 however (N=103), the *2 and *3 alleles become significantly associated with an increase in the number of hypoglycemic events per patient. Patients reported blood glucose levels once a week, and if they had signs or symptoms of hypoglycemic events. Hypoglycemia was defined according to the American Diabetes Association symptoms and confirmed by blood glucose measurement of less than 3.9 mmol/l.
Note: the authors genotyped rs1799853 and consider the C allele to be equivalent to *2, and the C allele at rs1057910 to be equivalent to *3."	gliclazide; glimepiride; glipizide; gliquidone; glyburide
1183681025	rs4506565	PMCID:PMC3893755	TCF7L2	Allele T is associated with increased risk of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele A.	yes	= 0.05	941	494	European	Toxicity	false	Hydrochlorothiazide-induced diabetes. Hydrochlorothiazide (HCTZ)  treatment was defined as exposure to HCTZ with any dose or duration before diagnosis of NOD. The patients are part of the INVEST study with randomized treatment with either an atenolol-based or a verapamil sustained release (SR)-based antihypertensive strategy. Both treatment strategies included the possibility of HCTZ treatment at different steps of the treatment plan for BP control as necessary.	hydrochlorothiazide
1444667028	rs1063538	PMCID:PMC4236071	ADIPOQ	Genotypes CC + CT are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotype TT.	no	= 0.765	80		East Asian	Efficacy	false	"Response was defined as ""any decrease greater than (or equal to) 15%"" of glycated hemoglobin (HbA1C%)."	pioglitazone
981344236	rs658903	PMCID:PMC3529742	KCNJ1	Allele A is associated with decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele T.	yes	= 0.002	464		Latino	Toxicity	false	Caution: this is a A/T SNP in a gene on the minus chromosomal strand. In the paper association is given for the A (minor) allele, which appears to be already shown on the plus chromosomal strand.	hydrochlorothiazide
982032925	rs1799752	PMCID:PMC2352037	ACE	Genotype del/del is associated with increased resistance to captopril in people with Diabetes Mellitus as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	yes	= 0.01	35		Unknown	Efficacy	false	Patients with the del/del genotype had steeper decline in glomerular filtration rate (GFR) compared to the other genotypes, indicating a decline in renal function.	captopril
1448276427	rs4149056	PMID:27271184	SLCO1B1	Allele C is associated with increased response to rosiglitazone in people with Diabetes Mellitus as compared to allele T.	yes	= 0.04	444		Unknown	Efficacy	false	as measured by HbA1c reduction.	rosiglitazone
1448605385	rs12117078	PMID:26644205	CRTC2	Genotype GG is not associated with risk of Diabetes Mellitus when treated with cyclosporine or tacrolimus in people with Transplantation as compared to genotypes CC + CG.	no	= 0.18	156		European	Toxicity	false	No association with new-onset diabetes after transplantation (NODAT) in solid organ transplantation recipients.	cyclosporine; tacrolimus
1446903458	rs13376631	PMCID:PMC4525256	FMO1	Allele G is not associated with response to metformin in people with Diabetes Mellitus as compared to allele A.	no	= 0.13560	258		Unknown	Efficacy	false	EHR-linked and EHR-based phenotyping methods were used to study common variants within FMO5. Efficacy was assessed by A1c levels extracted from EHR records. The SNP was marginally significant after correction for multiple testing.	metformin
1450376146	rs7903146	PMID:21857094	TCF7L2	Genotypes CT + TT is not associated with risk of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	no	= 0.089	196		European	Toxicity	false	Post-transplant diabetes mellitus (PTDM). No significant association was seen in multivariate logistic regression when considering either early PTDM (up to 14 days from transplant) or late PTDM (later than 14 days from transplant).	tacrolimus
981344223	rs11600347	PMCID:PMC3529742	KCNJ1	Allele A is associated with increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele C.	yes	= 0.008	371		European	Toxicity	false	"The association is described as ""nominal significance"" in hispanics."	hydrochlorothiazide
1446903452	rs12752688	PMCID:PMC4525256		Allele T is not associated with response to metformin in people with Diabetes Mellitus as compared to allele C.	no	= 0.07885	258		Unknown	Efficacy	false	EHR-linked and EHR-based phenotyping methods were used to study common variants within FMO5. Efficacy was assessed by A1c levels extracted from EHR records.	metformin
1452828220	rs622342	PMID:39375343	SLC22A1	Allele A is associated with increased response to metformin in people with Diabetes Mellitus as compared to allele C.	yes	= 0.0013	292		European	Efficacy	false	"Among the tested variants, only rs622342 in SLC22A1 (variously also referred to as ""SLC2A1"" in the publication) was significantly associated with lower HbA1c in type II diabetes mellitus patients using metformin. Given the nucleotide base description of rs622342 in Table S1 as ""C>A"", it was assumed that A is the risk allele."	metformin
769255551	rs5030868	PMID:8562390	G6PD	Allele A (assigned as deficiency phenotype) is associated with Hemolysis when treated with glibenclamide in people with Diabetes Mellitus.	not stated		1		Unknown	Toxicity	false	Case study report of a single individual. Genotyped by molecular analysis. Patient had Type 2 diabetes.	glyburide
1449310660	rs1057910	PMCID:PMC5898372	CYP2C9	Allele C is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele A.	no	> 0.05	425		Latino	Efficacy	false	This is the defining SNP of CYP2C9*3	sulfonamides, urea derivatives
1449310666	rs5215	PMCID:PMC5898372	KCNJ11	Allele T is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele C.	no	> 0.05	425		Latino	Efficacy	false		sulfonamides, urea derivatives
1446903446	rs1920145	PMCID:PMC4525256		Allele C is not associated with response to metformin in people with Diabetes Mellitus as compared to allele T.	no	= 0.26530	258		Unknown	Efficacy	false	EHR-linked and EHR-based phenotyping methods were used to study common variants within FMO5. Efficacy was assessed by A1c levels extracted from EHR records.	metformin
1447987173	rs7754840	PMCID:PMC4854407	CDKAL1	Allele C is associated with increased response to Dipeptidyl peptidase 4 (DPP-4) inhibitors in people with Diabetes Mellitus as compared to allele G.	yes	= 0.01	426		East Asian	Efficacy	false	The SNP was significantly associated with improved response to DPP-4 inhibitors (as assayed by reductions in HbA1c). Most of the patients were on combination anti-diabetic agent (ADA) therapy, but the relationship was only significant for regimens that included DPP-4 (alone or in combination with other ADAs).	Dipeptidyl peptidase 4 (DPP-4) inhibitors
981344210	rs12795437	PMCID:PMC3529742	KCNJ1	Allele C is associated with increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele G.	yes	= 0.006	371		European	Toxicity	false	"Caution: this is a C/G SNP in a gene on the minus chromosomal strand. In the paper association is given for the C (minor) allele, which appears to be already shown on the plus chromosomal strand. 
The association is described as ""nominal significance"" in hispanics"	hydrochlorothiazide
1446903440	rs2076322	PMCID:PMC4525256		Allele G is not associated with response to metformin in people with Diabetes Mellitus as compared to allele A.	no	= 0.12270	258		Unknown	Efficacy	false	EHR-linked and EHR-based phenotyping methods were used to study common variants within FMO5. Efficacy was assessed by A1c levels extracted from EHR records.	metformin
1450376156	rs12255372	PMID:21857094	TCF7L2	Allele G is not associated with risk of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to allele T.	no	= 0.05	28	168	European	Toxicity	false	No significant association was seen for either early PTDM (up to 14 days from transplant) or late PTDM (later than 14 days from transplant)	tacrolimus
1449310672	rs12208357	PMCID:PMC5898372	SLC22A1	Allele T is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele C.	no	> 0.05	425		Latino	Efficacy	false		sulfonamides, urea derivatives
1446903431	rs7541245	PMCID:PMC4525256	FMO5	Allele A is associated with decreased response to metformin in people with Diabetes Mellitus as compared to allele C.	yes	= 0.00188	258		Unknown	Efficacy	false	EHR-linked and EHR-based phenotyping methods were used to study common variants within FMO5. Efficacy was assessed by A1c levels extracted from EHR records.	metformin
1447987188	rs7756992	PMCID:PMC4854407	CDKAL1	Allele G is associated with increased response to Dipeptidyl peptidase 4 (DPP-4) inhibitors in people with Diabetes Mellitus as compared to allele A.	yes	= 0.001	426		East Asian	Efficacy	false	The SNP was significantly associated with improved response to DPP-4 inhibitors (as assayed by reductions in HbA1c). Most of the patients were on combination anti-diabetic agent (ADA) therapy, but the relationship was only significant for regimens that included DPP-4 (alone or in combination with other ADAs).	Dipeptidyl peptidase 4 (DPP-4) inhibitors
1449310630	rs757110	PMCID:PMC5898372	ABCC8	Genotypes AA + CC is associated with increased response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to genotype AC.	yes	= 0.04	425		Latino	Efficacy	false	The AC genotype was associated with increased response to sulfonylureas (a greater than or equal to 7% decrease in Hb1Ac levels at least 3 months after beginning treatment).	sulfonamides, urea derivatives
1449190053	CYP2C19*17	PMID:28664816	CYP2C19	CYP2C19 *17/*17 is associated with decreased likelihood of Diabetes Mellitus when treated with clozapine in people with schizoaffective disorder and Schizophrenia.	yes	= 0.012	20	105	Multiple groups	Toxicity	false		clozapine
1449751727	rs529038948	PMCID:PMC6563124	CACNA1S	Allele A is associated with statin-related myopathy when treated with atorvastatin in people with Diabetes Mellitus, Hypertension and Obesity as compared to allele G.	no		1		American	Toxicity	false	Alleles complemented to plus chromosomal strand. While study looked at 76 subjects with severe statin-associated muscle symptoms and 50 statin-tolerant controls, then studied exam sequencing data in RYR1 and CACNA1S, most variants considered pathogenic were at very low frequency and were reported as case series not with statistics for overall risk.	atorvastatin
1448276377	CYP2C8*1; CYP2C8*3	PMID:27271184	CYP2C8	CYP2C8 *3 is associated with decreased response to rosiglitazone in people with Diabetes Mellitus as compared to CYP2C8 *1/*1.	yes	= 0.01	444		Unknown	Efficacy	false		rosiglitazone
1448605339	rs8450	PMID:26644205	CRTC2	Genotype AA is associated with increased risk of Diabetes Mellitus when treated with cyclosporine or tacrolimus in people with Transplantation as compared to genotypes AG + GG.	yes	= 0.01	281		European	Toxicity	false	The AA genotype was associated with an increased risk of new-onset diabetes after transplantation (NODAT) in solid organ transplantation recipients. There was a discovery sample (patients received either tacrolimus or cyclosporine), and two replication samples from the Swiss Transplant Cohort Study (STCS; patients received tacrolimus, cyclosporine or neither). Significant associations were seen in the discovery sample, the STCS first replication sample when only patients who received tacrolimus and had a deceased donor were considered, in the second replication sample when all patients were considered, and in the combined analysis when only patients who received tacrolimus and had a decreased donor were considered. In the combined STCS analysis, results were only significant in non-kidney transplant patients (kidney transplant patients p=0.62, OR=0.87 (0.5-1.52)).	cyclosporine; tacrolimus
1449310639	rs5219	PMCID:PMC5898372	KCNJ11	Genotype CT is associated with increased response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to genotypes CC + TT.	yes	= 0.018	425		Latino	Efficacy	false	The CT genotype was associated with increased response to sulfonylureas (a greater than or equal to 7% decrease in Hb1Ac levels at least 3 months after beginning treatment).	sulfonamides, urea derivatives
1448569497	rs62151109	PMID:28084903	CLASP1	Allele C is associated with increased likelihood of Cough when treated with Ace Inhibitors, Plain in people with Asthma, Diabetes Mellitus, Heart Failure, Hypertension and Pulmonary Disease, Chronic Obstructive as compared to allele T.	no	= 9.44E-8	124	1345	European	Toxicity	false	No SNPs in the GWAS met the threshold for Bonferroni correction but this had the strongest association. Assumed that minor allele is the risk allele.	Ace Inhibitors, Plain
1450377120	rs12255372	PMID:23041303	TCF7L2	Genotype GT is not associated with risk of Diabetes Mellitus when treated with tacrolimus in people with liver transplantation as compared to genotype GG.	no	= 0.716	25	100	East Asian	Toxicity	false	No significant association was seen when considering either DONOR or RECIPIENT genotype. New-onset diabetes mellitus (NODM).	tacrolimus
1452364100	CYP3A5*1; CYP3A5*3	PMID:38253626	CYP3A5	CYP3A5 *3/*3 is associated with increased likelihood of nephrotoxicity, Tremor or Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	yes	= 0.002	37	186	Near Eastern	Toxicity	true	"""In our study, we observed a significant association between the
CYP3A5*3 polymorphism and the occurrence of tacrolimus-related
adverse effects. This polymorphism seemed to be associated with
an increased occurrence of nephrotoxicity, tremors, and posttransplant diabetes. In agreement with our results, a study found
that recipients carrying at least one CYP3A5*1 allele develop less
significant nephrotoxicity than patients with CYP3A5*3/*3
genotype [42]. Patients carrying a CYP3A5*1 allele, with lower
C0, seem less exposed to tacrolimus; which probably protects
them against nephrotoxicity"" ""After adjusting for potential confounding factors (sex, smoking,
alcohol, diabetes, recipient age, MPA and co-medication), a lower
occurrence of nephrotoxicity, tremor and new-onset diabetes
associated with CYP3A5*1 allele ((OR = 0.70, 95% CI: 0.51–0.98,
p = 0.03); (OR = 0.57, 95%: 0.36–0.90, p = 0.01); (OR = 0.44, 95% CI:
0.25–0.74, p = 0.002) respectively)"""	tacrolimus
769171457	rs4341	PMID:19247266	ACE	Genotype GG is associated with increased risk of Diabetes Mellitus when treated with Thiazides, plain as compared to genotypes CC + CG.	yes	< 0.05	497	2633	European	Toxicity	false	This variant was referred to in the study as ACE G4656C or 4656+CT, and it was stated that the G corresponds to the deleted allele, and the C with the insertion allele. The study compared GG genotype OR; 2.49 (1.65-3.75)  p<0.05, with the CC/CG genotypes OR; 1.38 (1.08-1.78) p<0.05 and showed that carriers of GG had a significantly higher risk. The risk of GG carriers increased further when the defined daily dose was 1 or more: OR; 3.07 (1.94-4.84) p<0.05.	Thiazides, plain
1444666816	rs2241766	PMCID:PMC4236071	ADIPOQ	Genotype GT is associated with increased response to pioglitazone in people with Diabetes Mellitus as compared to genotype TT.	yes	= 0.001	80		East Asian	Efficacy	false	"Response was defined as ""any decrease greater than (or equal to) 15%"" of glycated hemoglobin (HbA1C%).  When comparing the response rates between patients with the GT versus TT genotypes, the GT genotypes were associated with a greater frequency of response (52.94% versus 12.7% p=0.001) as well as a greater decrease in HbA1c% as compared to patients with the TT genotype (1.15 versus 0.52 p=0.001). Logistic regression analysis showed that rs2241766 GT genotype was associated with response to pioglitazone. *Please note: there were no individuals of genotype GG."	pioglitazone
1449310654	rs1799853	PMCID:PMC5898372	CYP2C9	Allele T is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele C.	no	> 0.05	425		Latino	Efficacy	false	This is the defining SNP of CYP2C9*2	sulfonamides, urea derivatives
982033238	rs1799752	PMID:9551410	ACE	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to captopril in people with Diabetes Mellitus as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	yes	< 0.01	60		Unknown	Efficacy	false	Reduction in mean arterial blood pressure and albuminuria was significantly greater in those with the ATA.../ATA... genotype compared to the remaining genotypes. No significant differences in change of serum creatinine was seen between the groups. Patients were treated with captopril for 6 months.	captopril
1448569481	rs1495509	PMID:28084903	KCNIP4	Allele C is not associated with Cough when treated with Ace Inhibitors, Plain in people with Asthma, Diabetes Mellitus, Heart Failure, Hypertension and Pulmonary Disease, Chronic Obstructive as compared to allele T.	no	= 0.72	124	1345	European	Toxicity	false		Ace Inhibitors, Plain
1444666874	rs1501299	PMCID:PMC4236071	ADIPOQ	Genotypes GT + TT are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotype TT.	no	= 0.461	80		East Asian	Efficacy	false	"Response was defined as ""any decrease greater than (or equal to) 15%"" of glycated hemoglobin (HbA1C%)."	pioglitazone
1296666538	rs10213440	PMID:25327507	PPARGC1A	Allele T is not associated with response to metformin in people with Diabetes Mellitus as compared to allele C.	no	= 0.199	148		Unknown	Efficacy	false	Treatment success was defined as 1) achieving HbA1c <7 % and 2) absolute reduction in HbAlc after 6-months of metformin therapy. The relationships between genotypes and outcomes were evaluated using multivariate logistic and linear models.	metformin
1184470140	rs5215	PMID:24442125	KCNJ11	Allele C is not associated with decreased hemoglobin levels when exposed to glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.	no	= 0.805	156		European	Toxicity	false	Fasting blod sample was drawn to determine hemoglobin (A1c) levels. HbA1c was determined with immunoturbodimetric hemolytic automated analysis.	gliclazide; glimepiride; glipizide; gliquidone; glyburide
1184470143	rs5219	PMID:24442125	KCNJ11	Allele C is not associated with decreased hemoglobin levels when exposed to glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.	no	= 0.807	156		European	Toxicity	false	Fasting blod sample was drawn to determine hemoglobin (A1c) levels. HbA1c was determined with immunoturbodimetric hemolytic automated analysis/.	gliclazide; glimepiride; glipizide; gliquidone; glyburide
1448276404	CYP2C8*1; CYP2C8*3	PMID:27271184	CYP2C8	CYP2C8 *3 is not associated with response to pioglitazone in people with Diabetes Mellitus as compared to CYP2C8 *1/*1.	no	= 0.26	239		Unknown	Efficacy	false		pioglitazone
1450377112	rs11196205	PMID:23041303	TCF7L2	Genotype CG is not associated with risk of Diabetes Mellitus when treated with tacrolimus in people with liver transplantation as compared to genotype GG.	no	= 0.875	25	100	East Asian	Metabolism/PK,Toxicity	false	No significant association was seen when considering either DONOR or RECIPIENT genotype. New-onset diabetes mellitus (NODM).	tacrolimus
1184470130	rs5219	PMID:24442125	KCNJ11	Allele C is not associated with dose of glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.	no	= 0.452	156		European	Dosage	false		gliclazide; glimepiride; glipizide; gliquidone; glyburide
1184470133	rs757110	PMID:24442125	ABCC8	Allele C is not associated with dose of glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele A.	no	= 0.551	156		European	Dosage	false		gliclazide; glimepiride; glipizide; gliquidone; glyburide
1448276415	CYP2C8*1; CYP2C8*3	PMID:27271184	CYP2C8	CYP2C8 *3 is not associated with Weight gain when treated with pioglitazone in people with Diabetes Mellitus as compared to CYP2C8 *1/*1.	no	= 0.34	239		Unknown	Toxicity	false		pioglitazone
1184470122	rs757110	PMID:24442125	ABCC8	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele A.	no	= 0.945	156		European	Other	false	The authors report that the C allele is not associated with the number of hypoglycemic events per patient over a period of three months when looking at the whole group (N=156) or when looking at the subset of patients over 60 (N=103). Patients reported blood glucose levels once a week, and if they had signs or symptoms of hypoglycemic events.Hypoglycemia was defined according to the American Diabetes Association symptoms and confirmed by blood glucose measurement of less than 3.9 mmol/l.	gliclazide; glimepiride; glipizide; gliquidone; glyburide
1184470125	rs5215	PMID:24442125	KCNJ11	Allele C is not associated with dose of glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.	no	= 0.348	156		European	Dosage	false		gliclazide; glimepiride; glipizide; gliquidone; glyburide
1448276391	CYP2C8*1; CYP2C8*3	PMID:27271184	CYP2C8	CYP2C8 *3 is associated with decreased Weight gain when treated with rosiglitazone in people with Diabetes Mellitus as compared to CYP2C8 *1/*1.	yes	= 0.02	444		Unknown	Toxicity	false		rosiglitazone
1451216520	rs72552763	PMCID:PMC5898372	SLC22A1	Allele del is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele GAT.	no	> 0.05	425		Latino	Efficacy	false	described as Met420Del in paper.	sulfonamides, urea derivatives
1450377097	rs7903146	PMID:23041303	TCF7L2	Genotype CT is not associated with risk of Diabetes Mellitus when treated with tacrolimus in people with liver transplantation as compared to genotype CC.	no	= 0.302	25	100	East Asian	Toxicity	false	No significant association was seen when considering either DONOR or RECIPIENT genotype. New-onset diabetes mellitus (NODM).	tacrolimus
1184470114	rs5215	PMID:24442125	KCNJ11	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.	no	= 0.960	156		European	Other	false	The authors report that the C allele is not associated with the number of hypoglycemic events per patient over a period of three months when looking at the whole group (N=156) or when looking at the subset of patients over 60 (N=103). Patients reported blood glucose levels once a week, and additionally noted if they had signs or symptoms of hypoglycemic events. Hypoglycemia was defined according to the American Diabetes Association symptoms and confirmed by blood glucose measurement of less than 3.9 mmol/l.	gliclazide; glimepiride; glipizide; gliquidone; glyburide
1448256681	rs8192675	PMCID:PMC5007158	SLC2A2	Allele C is associated with increased response to metformin in people with Diabetes Mellitus as compared to allele T.	yes	= 2.6e-8	10577		European	Efficacy	false	The C allele of rs8192675 was associated with a 0.17% (P = 6.6 × 10-14) greater metformin-induced reduction in hemoglobin A1c (HbA1c) in 10,577 participants of European ancestry.	metformin
1184470119	rs5219	PMID:24442125	KCNJ11	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.	no	= 0.930	156		European	Other	false	The authors report that the C allele is not associated with the number of hypoglycemic events per patient over a period of three months when looking at the whole group (N=156) or when looking at the subset of patients over 60 (N=103). Patients reported blood glucose levels once a week, and if they had signs or symptoms of hypoglycemic events. Hypoglycemia was defined according to the American Diabetes Association symptoms and confirmed by blood glucose measurement of less than 3.9 mmol/l.	gliclazide; glimepiride; glipizide; gliquidone; glyburide